Literature DB >> 11517272

Pharmacological modulation of behavioral and neuronal correlates of repetition priming.

C M Thiel1, R N Henson, J S Morris, K J Friston, R J Dolan.   

Abstract

In this experiment we address the pharmacological modulation of repetition priming, a basic form of learning, using event-related functional magnetic resonance imaging. We measured brain activity in a word-stem completion paradigm in which, before study, volunteers were given either placebo, lorazepam (2 mg orally), or scopolamine (0.4 mg, i.v.). Relative to placebo, both drugs attenuated the behavioral expression of priming. Repetition was associated with a decreased neuronal response in left extrastriate, left middle frontal, and left inferior frontal cortices in the placebo group. Both drugs abolished these "repetition suppression" effects. By showing a concurrence of behavioral and neuronal modulations, the results suggest that GABAergic and cholinergic systems influence the neuronal plasticity necessary for repetition priming.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517272      PMCID: PMC6763113     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  48 in total

1.  Neuroimaging evidence for dissociable forms of repetition priming.

Authors:  R Henson; T Shallice; R Dolan
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

2.  Lorazepam impairs both visual and auditory perceptual priming.

Authors:  P Vidailhet; J M Danion; C Chemin; M Kazès
Journal:  Psychopharmacology (Berl)       Date:  1999-12       Impact factor: 4.530

3.  Regulation of cerebral blood flow response to somatosensory stimulation through the cholinergic system: a positron emission tomography study in unanesthetized monkeys.

Authors:  H Tsukada; T Kakiuchi; I Ando; H Shizuno; S Nakanishi; Y Ouchi
Journal:  Brain Res       Date:  1997-02-21       Impact factor: 3.252

4.  Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers.

Authors:  J M Danion; M A Zimmermann; D Willard-Schroeder; D Grangé; M Welsch; J L Imbs; L Singer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Functional changes in brain activity during priming in Alzheimer's disease.

Authors:  L Bäckman; O Almkvist; L Nyberg; J Andersson
Journal:  J Cogn Neurosci       Date:  2000-01       Impact factor: 3.225

6.  Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall.

Authors:  F Schifano; H V Curran
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

Review 7.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

8.  Activation of the hippocampus in normal humans: a functional anatomical study of memory.

Authors:  L R Squire; J G Ojemann; F M Miezin; S E Petersen; T O Videen; M E Raichle
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Scopolamine affects short-term memory but not inferior temporal neurons.

Authors:  E K Miller; R Desimone
Journal:  Neuroreport       Date:  1993-01       Impact factor: 1.837

10.  Unaware learning versus preserved learning in pharmacologic amnesia: similarities and differences.

Authors:  D Knopman
Journal:  J Exp Psychol Learn Mem Cogn       Date:  1991-09       Impact factor: 3.051

View more
  19 in total

1.  Functional MRI detection of pharmacologically induced memory impairment.

Authors:  Reisa Sperling; Douglas Greve; Anders Dale; Ronald Killiany; Jennifer Holmes; H Diana Rosas; Andrew Cocchiarella; Paul Firth; Bruce Rosen; Stephen Lake; Nicholas Lange; Carol Routledge; Marilyn Albert
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

2.  Neural mechanisms of repetition priming of familiar and globally unfamiliar visual objects.

Authors:  Anja Soldan; Christian Habeck; Yunglin Gazes; Yaakov Stern
Journal:  Brain Res       Date:  2010-05-05       Impact factor: 3.252

Review 3.  Potential of functional MRI as a biomarker in early Alzheimer's disease.

Authors:  Reisa Sperling
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

4.  The first candidate gene for dyslexia: Turning the page of a new chapter of research.

Authors:  Elena L Grigorenko
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-23       Impact factor: 11.205

5.  Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects.

Authors:  Bianca Voss; Renate Thienel; Martina Reske; Thilo Kellermann; Abigail J Sheldrick; Sarah Halfter; Katrin Radenbach; Nadim J Shah; Ute Habel; Tilo T J Kircher
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10-18       Impact factor: 5.270

6.  Reduced habituation in patients with schizophrenia.

Authors:  Lisa E Williams; Jennifer Urbano Blackford; Andrew Luksik; Isabel Gauthier; Stephan Heckers
Journal:  Schizophr Res       Date:  2013-11-05       Impact factor: 4.939

Review 7.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

8.  Using arterial spin labeling perfusion MRI to explore how midazolam produces anterograde amnesia.

Authors:  Peipeng Liang; Anna Manelis; Xiaonan Liu; Howard J Aizenstein; Ferenc Gyulai; Joseph J Quinlan; Lynne M Reder
Journal:  Neurosci Lett       Date:  2012-06-16       Impact factor: 3.046

9.  Repetition priming and cortical arousal in healthy aging and Alzheimer's disease.

Authors:  Amy E Kane; Elena K Festa; David P Salmon; William C Heindel
Journal:  Neuropsychologia       Date:  2015-02-18       Impact factor: 3.139

Review 10.  Advances in functional magnetic resonance imaging: technology and clinical applications.

Authors:  Bradford C Dickerson
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.